Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

321. Prevalence, incidence and associated mortality of cardiovascular disease in patients with chronic kidney disease in low- and middle-income countries: a protocol for a systematic review and meta-analysis. (Full text)

Prevalence, incidence and associated mortality of cardiovascular disease in patients with chronic kidney disease in low- and middle-income countries: a protocol for a systematic review and meta-analysis. Chronic kidney disease (CKD) is a global public health problem, with cardiovascular disease (CVD) being the major cause of mortality in these patients. Despite a high burden of CKD among patients in low/middle-income countries (LMICs), evidence on the distribution of CVD among these patients

2017 BMJ open PubMed abstract

322. Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease : A meta-analysis. (Abstract)

Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease : A meta-analysis. Paricalcitol, a selective activator of the vitamin D receptor (VDR), influences calcium and phosphorus homeostasis and bone metabolism. Whether paricalcitol reduces cardiovascular risk and protects renal function remains unclear. To systematically evaluate this in patients with chronic kidney disease (CKD), we conducted a meta-analysis of published randomized (...) controlled trials (RCTs).We searched MEDLINE, Embase, the Cochrane Library, and reference lists for RCTs comparing paricalcitol with placebo in stage 2-5 CKD (including pre-dialysis and renal replacement patients). The Cochrane quality assessment method was used to evaluate study quality. Results were summarized as risk ratios (RRs) for dichotomous outcomes or mean differences (MD) for continuous outcomes.We included 21 studies comprising 1894 patients. Compared to placebo, paricalcitol reduced the risk

2017 Herz

323. Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis. (Abstract)

Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis. The aim of this meta-analysis was to assess the risks of chronic kidney disease (CKD) and/or end-stage kidney disease (ESRD) in patients who are taking proton-pump inhibitors (PPIs) and/or H2 receptor antagonists (H2RAs).Comprehensive literature review was conducted utilizing MEDLINE and EMBASE databases through April 2017 to identify all studies that investigated the risks of CKD

2017 Digestive diseases and sciences

324. Effectiveness of medical compared to multidisciplinary models of care, for patients' with pre-dialysis chronic kidney disease; A systematic review. (Abstract)

Effectiveness of medical compared to multidisciplinary models of care, for patients' with pre-dialysis chronic kidney disease; A systematic review. 27819978 2019 11 20 1838-2142 7 16 Suppl 2009 JBI library of systematic reviews JBI Libr Syst Rev Effectiveness of medical compared to multidisciplinary models of care, for patients' with pre-dialysis chronic kidney disease; A systematic review. 1-15 eng Journal Article Australia JBI Libr Syst Rev 101688957 1838-2142 2016 11 8 6 0 2009 1 1 0 0 2009

2017 JBI library of systematic reviews

325. Effectiveness of medical compared to multidisciplinary models of care for adult persons with pre-dialysis chronic kidney disease: a systematic review. (Abstract)

and in this study there was no difference in outcomes between multidisciplinary care and traditional care. The other three articles showed a positive impact on patient wellbeing and outcomes for those receiving multidisciplinary care, such as delay in the progression of their chronic kidney disease. Education of patients was shown to have a significant effect on the delay in time for patients initiating renal replacement therapy whether as peritoneal-dialysis, haemo-dialysis or transplantation. None (...) of the articles reported negative effects, reduced safety or poor outcomes for the patients receiving multidisciplinary care. Well controlled blood pressure, within treatment targets, appears to be an important factor in delaying the progression of their chronic kidney disease, although this did not reach statistical significance.Multidisciplinary care is deemed to be effective for adults with pre-dialysis chronic kidney disease. The effectiveness is shown as a delay in time to initiation of renal replacement

2017 JBI library of systematic reviews

326. Elevated bilirubin levels and risk of developing chronic kidney disease: a dose-response meta-analysis and systematic review of cohort studies. (Abstract)

Elevated bilirubin levels and risk of developing chronic kidney disease: a dose-response meta-analysis and systematic review of cohort studies. Previous studies have indicated the link of bilirubin levels and risk of developing chronic kidney disease (CKD); however, the findings were inconsistent.We searched for cohort studies examining bilirubin as an exposure and CKD as an outcome in the Medline, EMBASE, and Web of Science databases from inception through November 31, 2016. A generalized

2017 International urology and nephrology

327. Do Implantable Cardioverter Defibrillators Reduce Mortality in Patients With Chronic Kidney Disease at All Stages? (Full text)

Do Implantable Cardioverter Defibrillators Reduce Mortality in Patients With Chronic Kidney Disease at All Stages? The benefits of implantable cardioverter defibrillator (ICD) implantation in chronic kidney disease (CKD) patients with high sudden cardiac death (SCD) risk are uncertain. To clarify the effects of receiving an ICD in CKD patients, we conducted this meta-analysis to identify the effects of ICDs on patients with CKD, including those on dialysis. We searched the Cochrane library

2017 International heart journal PubMed abstract

328. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. (Full text)

Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Continuous erythropoiesis receptor activator (CERA) is a newer, longer acting ESA which might be preferred to other ESAs (epoetin or darbepoetin) based on its lower frequency of administration. Different dosing requirements and molecular characteristics of CERA compared with other ESAs may lead to different health outcomes (mortality, cardiovascular events, quality of life) in people with anaemia (...) and chronic kidney disease (CKD).To assess benefits and harms of CERA compared with other epoetins (darbepoetin alfa and epoetin alfa or beta) or placebo/no treatment or CERA with differing strategy of administration for anaemia in individuals with CKD.We searched the Cochrane Kidney and Transplant Specialised Register to 13 June 2017 through contact with the Information Specialist using search terms relevant to this review. Studies contained in the Specialised Register are identified through search

2017 Cochrane PubMed abstract

329. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. (Full text)

Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. Non-steroidal anti-inflammatory drugs (NSAIDs) are a common cause of adverse drug events (ADEs), but renal risks of NSAIDs are less well quantified than gastrointestinal and cardiac risks. This paper reports a systematic review of published population-based observational studies examining the risk of acute (...) kidney injury (AKI) associated with NSAIDs in community-dwelling adults and those with pre-existing chronic kidney disease (CKD).MEDLINE and EMBASE databases were searched until June 2016, and 3789 papers screened. Ten studies reporting NSAID risk of AKI in the general population were included in random effects meta-analysis, of which five additionally reported NSAID risk in people with CKD.In the general population, the pooled odds ratio (OR) of AKI for current NSAID exposure was 1.73 (95%CI 1.44

2017 BMC nephrology PubMed abstract

330. Hypertensive Kidney Injury and the Progression of Chronic Kidney Disease (Full text)

Hypertensive Kidney Injury and the Progression of Chronic Kidney Disease 28760941 2018 01 29 2018 11 13 1524-4563 70 4 2017 10 Hypertension (Dallas, Tex. : 1979) Hypertension Hypertensive Kidney Injury and the Progression of Chronic Kidney Disease. 687-694 10.1161/HYPERTENSIONAHA.117.08314 Griffin Karen A KA From the Hines VA Hospital, IL; and Loyola University Medical Center, Maywood, IL. kgriffi@lumc.edu. eng R01 DK040426 DK NIDDK NIH HHS United States R01 DK061653 DK NIDDK NIH HHS United (...) States Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Review 2017 07 31 United States Hypertension 7906255 0194-911X IM Disease Progression Humans Hypertension complications physiopathology Renal Insufficiency, Chronic etiology physiopathology 2017 8 2 6 0 2018 1 30 6 0 2017 8 2 6 0 ppublish 28760941 HYPERTENSIONAHA.117.08314 10.1161/HYPERTENSIONAHA.117.08314 PMC5599324 NIHMS891429 Curr Opin Nephrol Hypertens. 2012 Jan;21(1):1-6 22048724 Hypertension

2017 Hypertension (Dallas, Tex. : 1979) PubMed abstract

331. Altered Protein Composition of Subcutaneous Adipose Tissue in Chronic Kidney Disease (Full text)

Altered Protein Composition of Subcutaneous Adipose Tissue in Chronic Kidney Disease Loss of renal function is associated with high mortality from cardiovascular disease (CVD). Patients with chronic kidney disease (CKD) have altered circulating adipokine and nonesterified fatty acid concentrations and insulin resistance, which are features of disturbed adipose tissue metabolism. Because dysfunctional adipose tissue contributes to the development of CVD, we hypothesize that adipose tissue

2017 Kidney international reports PubMed abstract

332. Estimating One-Year Risk of Incident Chronic Kidney Disease: Retrospective Development and Validation Study Using Electronic Medical Record Data From the State of Maine (Full text)

Estimating One-Year Risk of Incident Chronic Kidney Disease: Retrospective Development and Validation Study Using Electronic Medical Record Data From the State of Maine Chronic kidney disease (CKD) is a major public health concern in the United States with high prevalence, growing incidence, and serious adverse outcomes.We aimed to develop and validate a model to identify patients at risk of receiving a new diagnosis of CKD (incident CKD) during the next 1 year in a general population.The study

2017 JMIR medical informatics PubMed abstract

333. Management of Severe Hyponatremia With a Custom Continuous Renal Replacement Therapy in an Infant With Newly Diagnosed Chronic Kidney Disease (Full text)

Management of Severe Hyponatremia With a Custom Continuous Renal Replacement Therapy in an Infant With Newly Diagnosed Chronic Kidney Disease 29270536 2019 02 26 2468-0249 2 6 2017 Nov Kidney international reports Kidney Int Rep Management of Severe Hyponatremia With a Custom Continuous Renal Replacement Therapy in an Infant With Newly Diagnosed Chronic Kidney Disease. 1254-1258 10.1016/j.ekir.2017.07.003 Gaudreault-Tremblay Marie-Michèle MM Division of Nephrology, The Hospital for Sick (...) of Toronto, Toronto, Ontario, Canada. Lemaire Mathieu M Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada. Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada. eng Case Reports 2017 07 20 United States Kidney Int Rep 101684752 2468-0249 2017 12 23 6 0 2017 12 23 6 0 2017 12 23 6 1 epublish 29270536 10.1016/j.ekir.2017.07.003 S2468-0249(17)30301-7 PMC5733878 J Am Soc Nephrol. 2012 Jul;23(7):1140-8 22626822 Pediatr Nephrol. 2010 Jul;25(7):1225-38

2017 Kidney international reports PubMed abstract

334. Risk of Colorectal Cancer in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. (Abstract)

Risk of Colorectal Cancer in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Association between chronic kidney disease and colorectal cancer (CRC) remains unclear.To assess the risk of CRC in patients with various chronic kidney diseases before and after kidney transplantation.Electronic databases were searched for cohort studies assessing the risk of CRC in patients with chronic kidney diseases. The primary outcome was the risk of CRC among studies that reported the risk (...) as standardized incidence rate (SIR).Fifty-four studies, including 1,208,767 patients that reported the incidence of CRC in chronic kidney diseases were identified. SIR of CRC were obtained from 17 retrospective cohort studies. Among the 3 studies (4 reports) that included chronic kidney disease patients without kidney transplantation, there was a significant increased risk of CRC (pooled SIR 1.18) (95% confidence interval, 1.01-1.37; P=0.033). High heterogeneity was seen (I=85.6%), and metaregression showed

2017 Journal of clinical gastroenterology

335. Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. (Full text)

Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. Some evidence suggests that chronic kidney disease is a risk factor for lower-extremity peripheral artery disease. We aimed to quantify the independent and joint associations of two measures of chronic kidney disease (estimated glomerular filtration rate [eGFR] and albuminuria) with the incidence of peripheral artery disease.In this collaborative meta (...) -analysis of international cohorts included in the Chronic Kidney Disease Prognosis Consortium (baseline measurements obtained between 1972 and 2014) with baseline measurements of eGFR and albuminuria, at least 1000 participants (this criterion not applied to cohorts exclusively enrolling patients with chronic kidney disease), and at least 50 peripheral artery disease events, we analysed adult participants without peripheral artery disease at baseline at the individual patient level with Cox

2017 The lancet. Diabetes & endocrinology PubMed abstract

336. Serum Potassium Levels and Risk of Sudden Cardiac Death Among Patients With Chronic Kidney Disease and Significant Coronary Artery Disease (Full text)

Serum Potassium Levels and Risk of Sudden Cardiac Death Among Patients With Chronic Kidney Disease and Significant Coronary Artery Disease Chronic kidney disease (CKD) patients have increased risks of sudden cardiac arrest and sudden cardiac death (SCA/SCD) that are not explained by traditional risk factors. We examined associations between serum potassium and SCA/SCD in a large cohort of patients with coronary artery disease (CAD) and moderate CKD.Among 22,009 patients who underwent cardiac (...) catheterization at our institution between 1999 and 2011, 6181 patients had an estimated glomerular filtration rate of ≤60 ml/min per 1.73 m2 and were not receiving renal replacement therapy. The risk of SCA/SCD and all-cause mortality associated with potassium concentration was evaluated at the time of cardiac catheterization (baseline) and most proximate to SCA/SCD events. Covariate-adjusted Cox models were used to examine relationships between baseline potassium measurements and outcomes. A propensity

2017 Kidney international reports PubMed abstract

337. Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure (Full text)

Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure This study investigated the relationship between the initial diuretic response to tolvaptan and clinical predictors for tolvaptan responders in patients with acute decompensated heart failure (ADHF).Patients (153) with ADHF (clinical scenario 2 or 3 with signs of fluid retention) who were administered tolvaptan were enrolled. Tolvaptan (15 or 7.5 mg) was administered for at least 7 days (...) to those patients in whom fluid retention was observed even after standard treatment. The maximum urine volume immediately after tolvaptan administration showed good correlations with the ejection fraction and estimated glomerular filtration rate that were independent predictors of the urine volume (UV) responders (≥1500 mL increase in urine volume). The diuretic response (in terms of maximum diuresis) diminished with advancing chronic kidney disease (CKD) stage and concomitant deterioration

2017 ESC heart failure PubMed abstract

338. Effectiveness of pay-for-performance for chronic kidney disease patients on hemodialysis: a systematic review protocol. (Abstract)

Effectiveness of pay-for-performance for chronic kidney disease patients on hemodialysis: a systematic review protocol. The objective of this review is to assess the evidence on the effectiveness of implementation of a pay-for-performance program on clinical outcomes in the adult chronic kidney disease (CKD) patient receiving hemodialysis.The review question is: What is the effectiveness of implementation of a pay-for-performance program on clinical outcomes in the adult CKD patient receiving

2017 JBI database of systematic reviews and implementation reports

339. Effects of self-management on chronic kidney disease: A meta-analysis. (Abstract)

by using keywords: chronic kidney disease, end-stage renal disease, renal failure, dialysis, self-management, self-efficacy, empowerment, cognitive behavioral, and educational. The methodological quality of randomized controlled trials was assessed using the Cochrane Handbook. Data were analyzed using Comprehensive Meta-Analysis software 2.0.Eighteen randomized controlled trials met our inclusion criteria. The results revealed that the self-management program significantly enhanced the effects of self (...) Effects of self-management on chronic kidney disease: A meta-analysis. Self-management programs may facilitate the improvement of outcomes in medical, role, and emotional management and health-related quality of life in patients with chronic kidney disease. Studies on the effect of three self-management tasks have reported conflicting findings. In addition, systematic reviews are unavailable.This study evaluated the effects of self-management programs on medical, role, and emotional management

2017 International journal of nursing studies

340. Chronic kidney disease and the global NCDs agenda (Full text)

Chronic kidney disease and the global NCDs agenda 29225940 2019 01 31 2059-7908 2 2 2017 BMJ global health BMJ Glob Health Chronic kidney disease and the global NCDs agenda. e000380 10.1136/bmjgh-2017-000380 Neuen Brendon Lange BL Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia. Renal and Metabolic Division, George Institute for Global Health, Sydney, Australia. Chadban Steven James SJ Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia (...) . Charles Perkins Centre, University of Sydney, Sydney, Australia. Demaio Alessandro Rhyl AR World Health Organization, Geneva, Switzerland. Johnson David Wayne DW Centre for Kidney Disease Research, University of Queensland, Brisbane, Australia. Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia. Translational Research Institute, Brisbane, Australia. Perkovic Vlado V Renal and Metabolic Division, George Institute for Global Health, Sydney, Australia. Department of Renal Medicine

2017 BMJ global health PubMed abstract